- Home
- GILD vs APP Comparison
GILD vs APP Comparison
Compare GILD & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- APP
- Stock Information
- Founded
- GILD 1987
- APP 2012
- Country
- GILD United States
- APP United States
- Employees
- GILD N/A
- APP N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- APP EDP Services
- Sector
- GILD Health Care
- APP Technology
- Exchange
- GILD Nasdaq
- APP Nasdaq
- Market Cap
- GILD 119.7B
- APP 127.6B
- IPO Year
- GILD 1992
- APP 2021
- Fundamental
- Price
- GILD $109.95
- APP $415.31
- Analyst Decision
- GILD Buy
- APP Buy
- Analyst Count
- GILD 27
- APP 20
- Target Price
- GILD $101.88
- APP $398.05
- AVG Volume (30 Days)
- GILD 7.6M
- APP 6.1M
- Earning Date
- GILD 02-11-2025
- APP 02-12-2025
- Dividend Yield
- GILD 2.87%
- APP N/A
- EPS Growth
- GILD N/A
- APP 363.16
- EPS
- GILD 0.38
- APP 4.53
- Revenue
- GILD $28,754,000,000.00
- APP $4,709,248,000.00
- Revenue This Year
- GILD $0.82
- APP $22.06
- Revenue Next Year
- GILD $3.21
- APP $21.45
- P/E Ratio
- GILD $289.34
- APP $91.59
- Revenue Growth
- GILD 6.04
- APP 43.44
- 52 Week Low
- GILD $62.07
- APP $57.09
- 52 Week High
- GILD $111.03
- APP $525.15
- Technical
- Relative Strength Index (RSI)
- GILD 75.82
- APP 53.47
- Support Level
- GILD $94.56
- APP $366.96
- Resistance Level
- GILD $106.69
- APP $519.79
- Average True Range (ATR)
- GILD 2.29
- APP 32.08
- MACD
- GILD 1.15
- APP 4.65
- Stochastic Oscillator
- GILD 93.47
- APP 37.57
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About APP Applovin Corporation
AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.